(lp0
S'SciClone Pharmaceuticals: Beyond The Death Of A Sales Process Seeking Alpha - Feb 2, 2017 SciClone Pharmaceuticals  is a revenue-generating pharmaceutical company with a portfolio of HBV/HCV, oncology, anti-infection and cardiovascular drug candidates.'
p1
aS"Why SciClone Pharmaceuticals, Inc. Is Surging Higher Motley Fool - Mar 12, 2015 Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis."
p2
aS'SciClone Confirms Receipt Of Unsolicited Proposal From GL Capital And ABG ... PR Newswire  - Nov 14, 2016 FOSTER CITY, Calif., Nov. 14, 2016 /PRNewswire/ -- SciClone Pharmaceuticals, Inc.   today confirmed that it has received an unsolicited, nonbinding proposal from a consortium led by GL Capital Management GP Limited and&nbsp;...'
p3
aS"Why SciClone Pharmaceuticals Is Soaring Today Motley Fool - Nov 10, 2015 So what: SciClone Pharmaceuticals' Zadaxin is an immune stimulating drug that is used to treat hepatitis B. The drug, which isn't available in the United States, is sold primarily in China, which is home to roughly one third of the globe's hepatitis B ..."
p4
aS'SciClone Pharmaceuticals Inc. SCLN  Wall Street Journal - Feb 12, 2011 News SciClone Pharmaceuticals Inc.SCLN. Significant News Only. 03/06/17; Press Release. SciClone Reports 2016 Financial Results And 2017 Outlook.'
p5
aS"Insider Trading Activity SciClone Pharmaceuticals, Inc.   CEO ... Market Exclusive - Feb 24, 2017 Friedhelm Blobel , CEO of SciClone Pharmaceuticals, Inc.  reportedly Sold 39,177 shares of the company's stock at an average price of 9.83 for a total transaction amount of $385,109.91 SEC Form."
p6
aS'SciClone Announces Final Resolution With The Securities And Exchange ... PR Newswire  - Feb 4, 2016 FOSTER CITY, Calif., Feb. 4, 2016 /PRNewswire/ -- SciClone Pharmaceuticals, Inc.   today announced it has entered into a settlement agreement with the United States Securities and Exchange Commission  fully&nbsp;...'
p7
aS'Sciclone Pharmaceuticals Inc  President &amp; CEO Friedhelm Blobel Sold $5 ... Nasdaq - Aug 19, 2016 SciClone Pharmaceuticals Inc is a specialty pharmaceutical company with a substantial commercial business in China and a product portfolio of therapies for oncology, infectious diseases and cardiovascular disorders.'
p8
aS"SciClone Pharmaceuticals, Inc.  CEO Friedhelm Blobel Sells 3087 Shares Chaffey Breeze - Mar 9, 2017 SciClone Pharmaceuticals logo SciClone Pharmaceuticals, Inc.  CEO Friedhelm Blobel sold 3,087 shares of the company's stock in a transaction dated Monday, March 6th.Sciclone Pharmaceuticals Inc  Files Form 4 Insider Selling : Friedhelm ... - Energy Index"
p9
aS'SciClone Pharmaceuticals To Report 2015 Financial Results On March 10, 2016 PR Newswire  - Feb 22, 2016 FOSTER CITY, Calif., Feb. 22, 2016 /PRNewswire/ -- SciClone Pharmaceuticals, Inc.  today announced that it plans to report financial results for the fourth quarter and full year 2015 on Thursday, March 10, 2016.'
p10
a.